Bank of America Corp. lowered shares of The Advisory Board Co. (NASDAQ:ABCO) from a buy rating to an underperform rating in a report published on Monday.

Other equities analysts have also recently issued research reports about the stock. Barclays PLC boosted their price objective on shares of The Advisory Board from $44.00 to $50.00 and gave the company an overweight rating in a research report on Friday, September 30th. Canaccord Genuity set a $50.00 price objective on shares of The Advisory Board and gave the company a buy rating in a research report on Wednesday, September 28th. Zacks Investment Research cut shares of The Advisory Board from a hold rating to a sell rating in a research report on Monday, October 17th. William Blair restated an outperform rating on shares of The Advisory Board in a research report on Tuesday, September 27th. Finally, Credit Suisse Group AG restated a buy rating and issued a $50.00 price objective on shares of The Advisory Board in a research report on Friday, September 16th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. The Advisory Board currently has an average rating of Buy and a consensus price target of $43.25.

Analyst Recommendations for The Advisory Board (NASDAQ:ABCO)

The Advisory Board (NASDAQ:ABCO) opened at 34.35 on Monday. The Advisory Board has a 12 month low of $18.87 and a 12 month high of $54.83. The company’s market cap is $1.38 billion. The company has a 50-day moving average of $41.57 and a 200 day moving average of $38.34.

The Advisory Board (NASDAQ:ABCO) last issued its earnings results on Tuesday, November 1st. The company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by $0.12. The business earned $200.50 million during the quarter, compared to analysts’ expectations of $203.35 million. The Advisory Board had a positive return on equity of 11.49% and a negative net margin of 5.77%. The Advisory Board’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 EPS. On average, equities analysts forecast that The Advisory Board will post $1.83 earnings per share for the current fiscal year.

In other news, insider Cormac F. Miller sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $43.04, for a total value of $64,560.00. Following the transaction, the insider now owns 18,987 shares in the company, valued at $817,200.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Evan R. Farber sold 2,924 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $40.95, for a total transaction of $119,737.80. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ABCO. Rail Splitter Capital Management LLC purchased a new position in shares of The Advisory Board during the second quarter valued at about $4,187,000. Ngam Advisors L.P. bought a new position in The Advisory Board during the second quarter valued at $423,000. Rice Hall James & Associates LLC boosted its position in The Advisory Board by 1.5% in the second quarter. Rice Hall James & Associates LLC now owns 360,064 shares of the company’s stock valued at $12,743,000 after buying an additional 5,322 shares during the last quarter. Confluence Investment Management LLC boosted its position in The Advisory Board by 1,192.7% in the second quarter. Confluence Investment Management LLC now owns 614,292 shares of the company’s stock valued at $21,740,000 after buying an additional 566,772 shares during the last quarter. Finally, Stoneridge Investment Partners LLC bought a new position in The Advisory Board during the second quarter valued at $2,287,000.

The Advisory Board Company Profile

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

5 Day Chart for NASDAQ:ABCO

Receive News & Stock Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related stocks with our FREE daily email newsletter.